IMGN

ImmunoGen, Inc. (IMGN) | Rumor.io

ImmunoGen

IMGN

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)74%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about IMGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

May 28

ImmunoGen, Inc. ($IMGN) is a privacy-focused AI company with real utility, sustainable products, and low market cap.
The company is seen as a strong contender for the next AI wave, which will reward useful projects over hyped ones.
Investors are staking conviction on $IMGN due to its actual utility, sustainable products, and focus on real infrastructure for the AI era.

Generated by AI

Sentiment

Of the messages about IMGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	25% -69.12	75.35% -8.13
Bearish	0%	0%	75% +69.12	24.65% +8.13

Bullish· Dec 4

ImmunoGen's ($IMGN) stock price could potentially break through the $16 barrier, following a similar pattern to its previous successful breakout.
A large buyer has been actively purchasing $IMGN shares, driving the price upwards, and market makers are being asked to send the stock to $30.5.
The acquisition of $IMGN by AbbVie Inc. ($ABBV) for around $10 billion is expected to close in mid-2024, representing a "great price" for ImmunoGen shareholders.

Bearish· Dec 1

The company has a history of inefficiency and poor decision-making, as evidenced by its 30-year lack of commercial products and ongoing insider selling.
The recent insider selling has likely had a negative impact on the company's stock price, with some individuals leaving significant amounts of money on the table.
The stock has a high short interest, with 10.1% of shares being shorted leading up to the buyout announcement, which could potentially lead to a significant price drop.

Generated by AI

Topics

Of the messages about IMGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	0.8%
Macro	—	—	0%	0%
Earnings	—	—	0%	0%
Controversies	—	—	0%	0%
Announcements	—	—	100%	98.81%
Analysts	—	—	0%	0.4%

Earnings· Jul 31

ImmunoGen, Inc. (IMGN) reported Q2 EPS of -$0.02, beating estimates of -$0.16.
The company's revenue was $83.15M, beating estimates of $42.84M, representing a 485.9% year-over-year increase.
ImmunoGen guided FY23 revenue above consensus, with operating expenses expected to be between $350M and $365M.

Analysts· Nov 16

ImmunoGen, Inc. (IMGN) has received positive analyst updates, with multiple firms raising their price targets.
Analysts at HC Wainwright, BMO Capital, and Canaccord Genuity have upgraded their price targets for IMGN, with the highest target set at $20.
The upgrades are driven by the company's potential for growth, particularly with the upcoming confirmatory readout of its Mirv launch.

Announcements· Feb 12

AbbVie has completed its acquisition of ImmunoGen for $31.26 per share, with an estimated equity value of $10.1 billion.
The acquisition is expected to be accretive to AbbVie's diluted EPS starting in 2027 and significantly accretive over the long-term.
AbbVie has revised its Q1 earnings outlook downward by $0.04 due to the acquisition, and reaffirmed its FY 2024 adjusted EPS range of $11.05-11.25.

Technical Analysis· May 4

IMGN has completed a stage 2 breakout from last week's newsletter, resulting in a massive follow-through today.
The stock's vwap has broken under 13, and a gap is expected to be filled, potentially leading to a price drop to $6.
IMGN's technical indicators are bearish, including a bearish RSI divergence on the 5-minute chart, a triple top formation around $13, and a possible SNAP-BACK move in the coming days.

Generated by AI

Community

Of the messages about IMGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	68.97%	79.68%
Newcomers	—	—	31.03%	20.32%

Regulars· Feb 8

The 30-day waiting period for the merger between ImmunoGen and AbbVie has expired, with the deal expected to close on or around February 12, 2024.
ImmunoGen's stock price has been rising, with a 5.7% increase premarket, as investors anticipate the merger's closure.
Analysts and investors are closely watching the AbbVie merger, with some initiating coverage on ImmunoGen and expressing optimism about the company's prospects.

Newcomers· Dec 4

New traders are using tools like Unusual Whales to gain insights and make trades, with some having successful wins on assets like IMGN.
The cost of goods sold (COGS) for cancer treatments like IMGN's product is significantly higher than for in-vivo CRISPR programs, affecting multiples in mergers and acquisitions.
Analyst consensus estimates for IMGN's sales may be overly optimistic, and AbbVie's due diligence may not have considered these estimates in their acquisition decision.

Generated by AI

Also Discussed

Investors talking about IMGN also mention

#	Name	Attention
1	SGEN - Seagen Inc.	——
2	MRTX - Mirati Therapeutics, Inc.	——
3	BPMC - Blueprint Medicines Corporation	——
4	MRNS - Marinus Pharmaceuticals, Inc.	——
5	TG Therapeutics Inc.TGTX	0.01%+0
6	Incyte Corp.INCY	0%new
7	FOLD - Amicus Therapeutics, Inc.	——
8	BLCM - Bellicum Pharmaceuticals, Inc.	——
9	Fate Therapeutics Inc.FATE	0%new
10	Sutro Biopharma Inc.STRO	0%new

ImmunoGen, Inc.

Location

Social

What share of all stock conversation is about IMGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

May 28

ImmunoGen, Inc. ($IMGN) is a privacy-focused AI company with real utility, sustainable products, and low market cap.
The company is seen as a strong contender for the next AI wave, which will reward useful projects over hyped ones.
Investors are staking conviction on $IMGN due to its actual utility, sustainable products, and focus on real infrastructure for the AI era.

Generated by AI

Sentiment

Of the messages about IMGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	25% -69.12	75.35% -8.13
Bearish	0%	0%	75% +69.12	24.65% +8.13

Bullish· Dec 4

ImmunoGen's ($IMGN) stock price could potentially break through the $16 barrier, following a similar pattern to its previous successful breakout.
A large buyer has been actively purchasing $IMGN shares, driving the price upwards, and market makers are being asked to send the stock to $30.5.
The acquisition of $IMGN by AbbVie Inc. ($ABBV) for around $10 billion is expected to close in mid-2024, representing a "great price" for ImmunoGen shareholders.

Bearish· Dec 1

The company has a history of inefficiency and poor decision-making, as evidenced by its 30-year lack of commercial products and ongoing insider selling.
The recent insider selling has likely had a negative impact on the company's stock price, with some individuals leaving significant amounts of money on the table.
The stock has a high short interest, with 10.1% of shares being shorted leading up to the buyout announcement, which could potentially lead to a significant price drop.

Generated by AI

Topics

Of the messages about IMGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	0.8%
Macro	—	—	0%	0%
Earnings	—	—	0%	0%
Controversies	—	—	0%	0%
Announcements	—	—	100%	98.81%
Analysts	—	—	0%	0.4%

Earnings· Jul 31

ImmunoGen, Inc. (IMGN) reported Q2 EPS of -$0.02, beating estimates of -$0.16.
The company's revenue was $83.15M, beating estimates of $42.84M, representing a 485.9% year-over-year increase.
ImmunoGen guided FY23 revenue above consensus, with operating expenses expected to be between $350M and $365M.

Analysts· Nov 16

ImmunoGen, Inc. (IMGN) has received positive analyst updates, with multiple firms raising their price targets.
Analysts at HC Wainwright, BMO Capital, and Canaccord Genuity have upgraded their price targets for IMGN, with the highest target set at $20.
The upgrades are driven by the company's potential for growth, particularly with the upcoming confirmatory readout of its Mirv launch.

Announcements· Feb 12

AbbVie has completed its acquisition of ImmunoGen for $31.26 per share, with an estimated equity value of $10.1 billion.
The acquisition is expected to be accretive to AbbVie's diluted EPS starting in 2027 and significantly accretive over the long-term.
AbbVie has revised its Q1 earnings outlook downward by $0.04 due to the acquisition, and reaffirmed its FY 2024 adjusted EPS range of $11.05-11.25.

Technical Analysis· May 4

IMGN has completed a stage 2 breakout from last week's newsletter, resulting in a massive follow-through today.
The stock's vwap has broken under 13, and a gap is expected to be filled, potentially leading to a price drop to $6.
IMGN's technical indicators are bearish, including a bearish RSI divergence on the 5-minute chart, a triple top formation around $13, and a possible SNAP-BACK move in the coming days.

Generated by AI

Community

Of the messages about IMGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	68.97%	79.68%
Newcomers	—	—	31.03%	20.32%

Regulars· Feb 8

The 30-day waiting period for the merger between ImmunoGen and AbbVie has expired, with the deal expected to close on or around February 12, 2024.
ImmunoGen's stock price has been rising, with a 5.7% increase premarket, as investors anticipate the merger's closure.
Analysts and investors are closely watching the AbbVie merger, with some initiating coverage on ImmunoGen and expressing optimism about the company's prospects.

Newcomers· Dec 4

New traders are using tools like Unusual Whales to gain insights and make trades, with some having successful wins on assets like IMGN.
The cost of goods sold (COGS) for cancer treatments like IMGN's product is significantly higher than for in-vivo CRISPR programs, affecting multiples in mergers and acquisitions.
Analyst consensus estimates for IMGN's sales may be overly optimistic, and AbbVie's due diligence may not have considered these estimates in their acquisition decision.

Generated by AI

ImmunoGen

Social

May 28

Sentiment

Bullish· Dec 4

Bearish· Dec 1

Topics

Earnings· Jul 31

Analysts· Nov 16

Announcements· Feb 12

Technical Analysis· May 4

Community

Regulars· Feb 8

Newcomers· Dec 4

Also Discussed

ImmunoGen, Inc.

Company Information

Location

Also Discussed

Social

May 28

Sentiment

Bullish· Dec 4

Bearish· Dec 1

Topics

Earnings· Jul 31

Analysts· Nov 16

Announcements· Feb 12

Technical Analysis· May 4

Community

Regulars· Feb 8

Newcomers· Dec 4